ATM and lung cancer: For example, ceralasertib resulted in prolonged cytotoxicity of cisplatin in ATM-deficient NSCLC cell lines.25 Even in cell lines with intact ATM signaling, the combination of cerale-sertib with cisplatin potentiates cytotoxicity.25 Similarly, berzosertib in combination with cisplatin demonstrated enhanced cytotoxicity both in lung cancer cell lines in vitro and in vivo in patient-derived primary lung xenografts.26 In 3 cisplatin-insensitive NSCLC models, berzosertib with cisplatin resulted in complete inhibition of tumor growth.